文献速递多重用药老年慢病共病管理安宁疗护

医生对老年人心血管药物减停处方的观点

Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.
PubMed 文献 · J Am Geriatr Soc · 2019-09-11

该研究为美国全国横断面调查,随机抽取老年科医生、普通内科医生和心内科医生各750名,评估其心血管药物减停处方的实践、原因和障碍。结果显示各专科超过80%的受访者近期考虑过减停,药物不良反应是最常见原因;在预期寿命有限时,老年科医生比心内科医生更倾向于考虑减停。

要点

  • 各专科超过80%的医生近期考虑过减停心血管药物,药物不良反应是最常见原因。
  • 预期寿命有限时,老年科医生最可能、心内科医生最不可能考虑减停心血管药物。
  • 减停障碍包括担心干扰其他医生的治疗计划和患者不情愿。

核心结论

  • 各专科减停心血管药物的障碍相似,但减停原因尤其在预期寿命有限时存在差异。
  • 实施减停需要改进医生与医生之间以及医生与患者之间的沟通流程。

研究设计与样本

  • 美国全国横断面调查,从美国内科医师学会随机抽取老年科医生、普通内科医生和心内科医生各750名进行电子问卷调查。

主要发现

  • 各专科超过80%的受访者报告近期考虑过减停心血管药物。
  • 药物不良反应是所有专科减停的最常见原因,老年科医生还常因预期寿命有限而减停。
  • 在预期寿命有限的假设病例中,老年科医生最可能考虑减停,心内科医生最不可能(所有P < .001)。
  • 复发性转移性癌症病例中,84%老年科医生、68%普通内科医生和45%心内科医生考虑减停。
  • 阿尔茨海默痴呆病例中,92%老年科医生、81%普通内科医生和59%心内科医生考虑减停。

关键数值与推荐

  • 减停障碍包括担心干扰其他医生的治疗计划和患者不情愿,各专科共享。
  • 预期寿命有限时考虑减停的比例:复发性转移性癌症为84%老年科医生、68%普通内科医生、45%心内科医生(P < .001)。
  • 阿尔茨海默痴呆为92%老年科医生、81%普通内科医生、59%心内科医生(P < .001)。
  • 显著功能受损为83%老年科医生、68%普通内科医生、45%心内科医生(P < .001)。

临床怎么用

  • 老年医学科医生应关注心血管药物减停,尤其在药物不良反应和预期寿命有限时。
  • 需加强医生间沟通以减少对干扰其他治疗计划的担忧,并与患者沟通减停理由以克服不情愿。

局限性

  • 调查应答率老年科医生26%、普通内科医生26%、心内科医生12%,可能存在无应答偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Guideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties. DESIGN: National cross-sectional survey. SETTING: Ambulatory. PARTICIPANTS: Random sample of geriatricians, general internists, and cardiologists from the American College of Physicians. MEASUREMENTS: Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases. RESULTS: In each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists). CONCLUSIONS: While barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Goyal P, Anderson TS, Bernacki GM, et al. Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults. J Am Geriatr Soc. 2019. PMID: 31509233. doi:10.1111/jgs.16157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。